Efficacy and safety of human urinary kallidinogenase for acute ischemic stroke: a meta-analysis
Open Access
- 20 September 2020
- journal article
- research article
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 48 (9)
Abstract
Objective: Human urinary kallidinogenase (HUK) is a glycoprotein extracted from human urine that is used to treat stroke by triggering positive regulation of the kallikrein–kinin system. Our aim was to evaluate the efficacy and safety of HUK treatment for acute ischemic stroke. Methods: We searched the online databases PubMed, Embase, Cochrane Library, Google Scholar, and China National Knowledge Infrastructure (CNKI) for papers published between January 2015 and December 2019. The quality of each trial was assessed using the Cochrane Reviewers’ Handbook. Randomized controlled trials of HUK in patients with acute ischemic stroke were included. Results: Sixteen trials with 1326 participants were included. The HUK injection groups had more neurological improvement than the control groups in National Institutes of Health Stroke Scale scores (mean difference, –1.65; 95% confidence interval [CI], –2.12 to –1.71) and clinical efficacy (1.30; 95% CI, 1.21 to 1.41). Subgroup analysis indicated that age may influence heterogeneity. Eleven trials reported adverse effects and there were no significant differences between the control and HUK groups (risk difference, 0.01; 95% CI, –0.02 to 0.04). Conclusions: HUK ameliorates neurological symptoms in stroke patients with few adverse effects. Further high-quality, large-scale randomized trials are needed to confirm these results.Keywords
This publication has 11 references indexed in Scilit:
- Treatment of Human Urinary Kallidinogenase Combined with Maixuekang Capsule Promotes Good Functional Outcome in Ischemic StrokeFrontiers in Physiology, 2018
- Analysis of treatment effect of urinary kallidinogenase combined with edaravone on massive cerebral infarctionBiomedical Reports, 2016
- Exogenous human urinary kallidinogenase increases cerebral blood flow in patients with acute ischemic strokeNeurosciences, 2016
- Human Urinary Kallidinogenase Improves Outcome of Stroke Patients by Shortening Mean Transit Time of Perfusion Magnetic Resonance ImagingJournal of Stroke and Cerebrovascular Diseases, 2015
- Human Urinary Kallidinogenase Promotes Angiogenesis and Cerebral Perfusion in Experimental StrokePLOS ONE, 2015
- Comparison of Therapeutic Effect of Recombinant Tissue Plasminogen Activator by Treatment Time after Onset of Acute Ischemic StrokeScientific Reports, 2015
- Study on the effect of urinary kallidinogenase after thrombolytic treatment for acute cerebral infarction.2015
- Efficacy and safety of human urinary kallidinogenase injection for acute ischemic stroke: A systematic reviewJournal of Evidence-Based Medicine, 2012
- Human Urinary Kallidinogenase Suppresses Cerebral Inflammation in Experimental Stroke and Downregulates Nuclear Factor-κBJournal of Cerebral Blood Flow & Metabolism, 2010
- Human Tissue Kallikrein: A New Bullet for the Treatment of IschemiaCurrent Pharmaceutical Design, 2003